Welcome in the research database

Tumor targeting with radiolabeled antibodies, peptides and nucleotides

Tumor targeting with radiolabeled antibodies, peptides and nucleotides for diagnosis and therapy of cancer is our motivation. Our research projects are clinically oriented, based generally on pre-clinical in vitro and in vivo studies.

In this field, two different radioimmunotherapies (RIT) of non-Hodgkin lymphoma (NHL) have been recently approved in the United States by the food and drug administration (FDA). These treatments represent a first successful application of radiolabeled antibodies in patients and provide a new treatment modality of this malignancy. Our group has been active in this field for many years studying radiolabeled antibodies in different other cancers. We currently continue this research at the pre-clinical and clinical level with anti-B-lymphoma antibodies.

As a second research direction, we develop a tumor targeting strategy with radiolabeled iododeoxyuridine, a thymidine analog, with support from the Swiss National Science Foundation. Iododeoxyuridine is incorporated in DNA during the synthesis phase of the cell cycle. Our project comprises the study of the cell cycle events around the S-phase and its pharmacological modulation aiming to favor the DNA-incorporation of radio-idododeoxyuridine. The approach revealed successful both in vitro and in vivo studies. We currently started with first therapy approaches in an animal model of human glioblastoma xenografts. A clinical diagnostic study is open aiming to establish the value of our experimental approach in glioblastoma patients.

We finally collaborate with different other centers in clinical research aiming to evaluate new peptide analogs that recognize specific receptors on cancer. We recently performed a first study of a radiolabeled Neurotensin analog in the frame of a European study implying international research collaboration. A new study aiming to evaluate new somatostatin analogs for diagnosis and therapy of somatostatin receptor positive tumors is in preparation in collaboration with Professor Helmut Maecke, Institute of Nuclear Medicine, Basel University Hospital.

Group's publications

High efficiency production and purification of 86Y based on electrochemical separation.
APPLIED RADIATION AND ISOTOPES : INCLUDING DATA, INSTRUMENTATION AND METHODS FOR USE IN AGRICULTURE, INDUSTRY AND MEDICINE
2009 vol. 67(4) pp. 523-529
LUKIC D, TAMBURELLA C, BUCHEGGER F, BEYER G.-J., COMOR J, SEIMBILLE Y

Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
2009 vol. 38(3) pp. 230-237
CIRSTOIU A, BUCHEGGER F, BOSSY L, KOSINSKI M, GURNY R, DELIE F

Local moderate magnetically induced hyperthermia using an implant formed in situ in a mouse tumor model
INTERNATIONAL JOURNAL OF HYPERTHERMIA
2009 vol. 25(3) pp. 229-239
LE RENARD PE, BUCHEGGER F, PETRI-FINK A, BOSMAN F, RUFENACHT D, HOFMANN H, DOELKER E, JORDAN O

Fluorodeoxyuridine mediated cell cycle synchronization in S-phase increases the Auger radiation cell killing with 125I-iododeoxyuridine.
NUKLEARMEDIZIN-NUCLEAR MEDICINE
2009 vol. 48(6) pp. 233-242
PERILLO-ADAMER F, KOSINSKI M, DUPERTUIS YM, VIERTL D, BISCHOFF A, BUCHEGGER F

Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
NUKLEARMEDIZIN-NUCLEAR MEDICINE
2009 vol. 48(1) pp. 1-9
STEINER CH, VEES H, ZAIDI H, WISSMEYER M, BERREBI O, KOSSOVSKY MP, KHAN H G, MIRALBELL R, RATIB O, BUCHEGGER F

Recurrence pattern after [(18)F]Fluoroethyltyrosine-Positron Emission Tomography-guided radiotherapy for high-grade glioma: A prospective study
RADIOTHERAPY AND ONCOLOGY
2009 vol. 93(3) pp. 586-592
WEBER D, CASANOVA N, ZILLI T, BUCHEGGER F, ROUZAUD M, NOUET P, VEES H, RATIB O, DIPASQUALE G, MIRALBELL R

[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma.
RADIATION ONCOLOGY
2008 vol. 3 pp. 44-44
WEBER DC AND AL.

Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.
THE ONCOLOGIST
2008 vol. 13(6) pp. 657-667
BUCHEGGER F, PRESS OW, DELALOYE AB, KETTERERN

F-18-choline and/or C-11-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (< 1 ng/mL) after radical prostatec tomy
BJU INTERNATIONAL
2007 vol. 99 pp. 1415-1420
VEES H, BUCHEGGER F, ALBRECHT S, KHAN H, HUSARIK D, ZAIDI H, SOLOVIEV D, HANY TF, MIRALBELL R

Radioimmunotherapy of follicular lymphoma: a step towards cure?
BULLETIN DU CANCER : JOURNAL DE LA SOCIETE FRANCAISE DU CANCER
2007 vol. 94(9) pp. 799-806
KETTERER N, BISCHOF DELALOYE, HELG C, LUTHI F, BUCHEGGER F

A pitfall of propidium iodide staining in fluorescence-activated cell sorting cell cycle analysis?
CANCER RESEARCH
2007 vol. 67 pp. 5576-5577
BUCHEGGER F, DUPERTUIS YM, PERILLO-ADAMER F

C-11-acetate PET in the early evaluation of prostate cancer recurrence
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
2007 vol. 34 pp. 185-196
ALBRECHT S, BUCHEGGER F, SOLOVIEV D, ZAIDI H, VEES H, KHAN HG, KELLER A, DELALOYE AB, RATIB O, MIRALBELL R

Differential tumor cell targeting of anti-HER2 (Herceptin (R)) and anti-CD20 (Mabthera (R)) coupled nanoparticles
INTERNATIONAL JOURNAL OF PHARMACEUTICS
2007 vol. 331 pp. 190-196
CIRSTOIU-HAPCA A, BOSSY-NOBS L, BUCHEGGER F, GURNY R, DELIE F

Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanoma
NUKLEARMEDIZIN-NUCLEAR MEDICINE
2007 vol. 46(6) pp. 244-251
WILLI JP, MATTER M, BUCHEGGER F, ANTONESCU C, GUGGISBERG D, CEROTTINI JP, KRISCHER J, BRAUN R, MARIE KURT A, ROCHE B, LEMOINE R, RIMOLDI D, LEJEUNE FJ, LIÉNARD D, BISCHOF DELALOYE A

Effect of an immunonutrient mix on human colorectal adenocarcinoma cell growth and viability
NUTRITION
2007 vol. 23 pp. 672-680
DUPERTUIS YM, BENAIS-PONT G, BUCHEGGER F, PICHARD C

Biodegradable nanoparticles for direct or two-step tumor immunotargeting
BIOCONJUGATE CHEMISTRY
2006 vol. 17 pp. 139-145
NOBS L, BUCHEGGER F, GURNY R, ALLEMANN E

Long-term complete responses after I-131-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma
BRITISH JOURNAL OF CANCER
2006 vol. 94 pp. 1770-1776
BUCHEGGER F, ANTONESCU C, DELALOYE AB, HELG C, KOVACSOVICS T, KOSINSKI M, MACH JP, KETTERER N

Auger radiation targeted into DNA: a therapy perspective
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
2006 vol. 33 pp. 1352-1363
BUCHEGGER F, PERILLO-ADAMER F, DUPERTUIS YM, DELALOYE AB

Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate I-125-iododeoxyuridine
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
2006 vol. 33 pp. 613-620
PERILLO-ADAMER F, DELALOYE AB, GENTON CS, SCHAFFLAND AO, DUPERTUIS YM, BUCHEGGER F

omega-3 Polyunsaturated fatty acids and ionizing radiation: combined cytotoxicity on human colorectal. adenocarcinoma cells
NUTRITION
2006 vol. 22 pp. 931-939
BENAIS-PONT G, DUPERTUIS YM, KOSSOVSKY MP, NOUET P, ALLAL AS, BUCHEGGER F, PICHARD C

Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
2005 vol. 32 pp. 943-951
C. ANTONESCU, A. BISCHOF DELALOYE, M. KOSINSKI, P. MONNIN, AO SCHAFFLAND, KETTERER N, GRANNAVEL C, KOVACSOVICS T., VERDUN FR, BUCHEGGER FRANZ

A new method of thermoablation with hot water vapour for localized tumors.
ANTICANCER RESEARCH
2004 vol. 24 pp. 2757-2563
HILTBRAND E, BELENGER JACQUES, BINZONI TIZIANO, BUCHEGGER FRANZ, COSTA MARIA CRISTINA, MEHIER H

Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2’-deoxy-2’-(fluoromethylene) cytidine and iododeoxyuridine.
EUROPEAN JOURNAL OF CANCER.
2004 vol. pp. 1572-1580
COUCKE PA, COTTIN E, AZRIA D, ADAMER F, DECOSTEROD LA, BUCHEGGER FRANZ, DO HP

Targeted alpha therapy in vivo : direct evidence for single cancer cell kill using 149Tb-Rituximab.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
2004 vol. 31 pp. 547-554
BEYER GERD-JURGEN, MIEDERER M, VRANIES DURIE S, COMOR JJ, KUNZI G, HARTLEY OLIVER, SENEKOWITSCH-SCHMIDTKE R, SOLOVIEV D, BUCHEGGER FRANZ, ISOLDE COLLABORATION

Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
2004 vol. 58 pp. 483-490
NOBS L, BUCHEGGER FRANZ, GURNY R, ALLÉMAN E

Highly efficient DNA incorporation of intratumourally injected [125I]iododoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts.
INTERNATIONAL JOURNAL OF CANCER
2004 vol. 110 pp. 145-149
BUCHEGGER FRANZ, ADAMER FLORENCE, SCHAFFLAND A O, KOSINSKI M, GRANNAVEL C, DUPERTUIS YVES, DE TRIBOLET NICOLAS, MACH JEAN-PIERRE, BISCHOF DELALOYE A

131I-Rituximab : relationship between immunoreactivity and specific activity.
JOURNAL OF NUCLEAR MEDICINE
2004 vol. 45 pp. 1784-1790
SCHAFFLAND AO, BUCHEGGER FRANZ, KOSINSKI MK, ANTONESCU C, PASCHOUD C, GRANNAVEL C, PELLIKKA R, BISCHOF DELALOYE A

Current methods for attaching targeting ligands to liposomes and nanoparticles.
JOURNAL OF PHARMACEUTICAL SCIENCES
2004 vol. 93 pp. 1980-1992
NOBS L, BUCHEGGER FRANZ, GURNY R, ALLÉMAN E

Effect of peroxisome proliferator-activated receptor g agonist rosiglitazone on dedifferentiated thyroid cancers.
NUCLEAR MEDICINE COMMUNICATIONS
2004 vol. 25 pp. 1183-1186
PHILIPS JC, PETITE CHRISTOPHE, WILLI JEAN-PIERRE, BUCHEGGER FRANZ, MEIER CHRISTOPH

The preparation of clinical grade 5’[123I]-iodo-2’-deoxyuridine and 5’[125I]-iodo-2’-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.
NUCLEAR MEDICINE COMMUNICATIONS
2004 vol. 25 pp. 461-468
SCHAFFLAND AO, BISCHOF DELALOYE A, KOSINSKI M, DUPERTUIS YVES, BUCHEGGER FRANZ

Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
2003 vol. 30(2) pp. 239-246
BUCHEGGER F, VIEIRA JM, BLAUEUENSTEIN P, DUPERTUIS YM, SCHAFFLAND AO, GRANNAVEL C, DE TRIBOLET N, SLOSMAN D, BISCHOF DELALOYE A

Radiolabeled Neurotensin analog, 99mTc-NT-XI, in ductal pancreatic adenocarcinoma patients.
JOURNAL OF NUCLEAR MEDICINE
2003 vol. 44 pp. 1649-1654
BUCHEGGER F, BONVIN F, KOSINSKI M, SCHAFFLAND AO, PRIOR J, REUBI JC, BLÄUENSTEIN P, TOURWE D, GARAYOA EG, DELALOYE AB

Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine
CANCER RESEARCH
2001 vol. 61 pp. 7971-7977
Y. DUPERTUIS, M. VASQUEZ, J.-P. MACH, N. DE TRIBOLET, C. PICHARD, D.O. SLOSMAN, F. BUCHEGGER

Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice
CANCER RESEARCH
1997 vol. 57 pp. 447-453
VOGEL CA, GALMICHE MC, BUCHEGGER FRANZ

Ablation of human colon carcinoma in nude mice by 131-I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab') 2 fragments
JOURNAL OF CLINICAL INVESTIGATION
1989 vol. 83 pp. 1449-1456
BUCHEGGER FRANZ, PFISTER C, FOURNIER K, PREVEL F, SCHREYER M, CARREL S, MACH JEAN-PIERRE

Research's domains




DATABASE-RESEARCH	GROUP OF CLINICAL PATIENT RESEARCH

Franz BUCHEGGER	Head of group CV	Research subject	Members of the group


	Links about the group Dr. F. BUCHEGGER HUG/ Dpt Radiologie Serv. de Médecine nucléaire Rue Gabrielle-Perret-Gentil 4 1211 Genève 14 Suisse Franz.Buchegger@hcuge.ch Tel.: 022/372.71.46 Fax: 022/372.71.69 Comments Pages updated the 17.11.2015		Reseach's subject \| Group's publications \| Research's domains Tumor targeting with radiolabeled antibodies, peptides and nucleotides Tumor targeting with radiolabeled antibodies, peptides and nucleotides for diagnosis and therapy of cancer is our motivation. Our research projects are clinically oriented, based generally on pre-clinical in vitro and in vivo studies. In this field, two different radioimmunotherapies (RIT) of non-Hodgkin lymphoma (NHL) have been recently approved in the United States by the food and drug administration (FDA). These treatments represent a first successful application of radiolabeled antibodies in patients and provide a new treatment modality of this malignancy. Our group has been active in this field for many years studying radiolabeled antibodies in different other cancers. We currently continue this research at the pre-clinical and clinical level with anti-B-lymphoma antibodies. As a second research direction, we develop a tumor targeting strategy with radiolabeled iododeoxyuridine, a thymidine analog, with support from the Swiss National Science Foundation. Iododeoxyuridine is incorporated in DNA during the synthesis phase of the cell cycle. Our project comprises the study of the cell cycle events around the S-phase and its pharmacological modulation aiming to favor the DNA-incorporation of radio-idododeoxyuridine. The approach revealed successful both in vitro and in vivo studies. We currently started with first therapy approaches in an animal model of human glioblastoma xenografts. A clinical diagnostic study is open aiming to establish the value of our experimental approach in glioblastoma patients. We finally collaborate with different other centers in clinical research aiming to evaluate new peptide analogs that recognize specific receptors on cancer. We recently performed a first study of a radiolabeled Neurotensin analog in the frame of a European study implying international research collaboration. A new study aiming to evaluate new somatostatin analogs for diagnosis and therapy of somatostatin receptor positive tumors is in preparation in collaboration with Professor Helmut Maecke, Institute of Nuclear Medicine, Basel University Hospital. Group's publications High efficiency production and purification of 86Y based on electrochemical separation. APPLIED RADIATION AND ISOTOPES : INCLUDING DATA, INSTRUMENTATION AND METHODS FOR USE IN AGRICULTURE, INDUSTRY AND MEDICINE 2009 vol. 67(4) pp. 523-529 LUKIC D, TAMBURELLA C, BUCHEGGER F, BEYER G.-J., COMOR J, SEIMBILLE Y Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2009 vol. 38(3) pp. 230-237 CIRSTOIU A, BUCHEGGER F, BOSSY L, KOSINSKI M, GURNY R, DELIE F Local moderate magnetically induced hyperthermia using an implant formed in situ in a mouse tumor model INTERNATIONAL JOURNAL OF HYPERTHERMIA 2009 vol. 25(3) pp. 229-239 LE RENARD PE, BUCHEGGER F, PETRI-FINK A, BOSMAN F, RUFENACHT D, HOFMANN H, DOELKER E, JORDAN O Fluorodeoxyuridine mediated cell cycle synchronization in S-phase increases the Auger radiation cell killing with 125I-iododeoxyuridine. NUKLEARMEDIZIN-NUCLEAR MEDICINE 2009 vol. 48(6) pp. 233-242 PERILLO-ADAMER F, KOSINSKI M, DUPERTUIS YM, VIERTL D, BISCHOFF A, BUCHEGGER F Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. NUKLEARMEDIZIN-NUCLEAR MEDICINE 2009 vol. 48(1) pp. 1-9 STEINER CH, VEES H, ZAIDI H, WISSMEYER M, BERREBI O, KOSSOVSKY MP, KHAN H G, MIRALBELL R, RATIB O, BUCHEGGER F Recurrence pattern after [(18)F]Fluoroethyltyrosine-Positron Emission Tomography-guided radiotherapy for high-grade glioma: A prospective study RADIOTHERAPY AND ONCOLOGY 2009 vol. 93(3) pp. 586-592 WEBER D, CASANOVA N, ZILLI T, BUCHEGGER F, ROUZAUD M, NOUET P, VEES H, RATIB O, DIPASQUALE G, MIRALBELL R [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. RADIATION ONCOLOGY 2008 vol. 3 pp. 44-44 WEBER DC AND AL. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. THE ONCOLOGIST 2008 vol. 13(6) pp. 657-667 BUCHEGGER F, PRESS OW, DELALOYE AB, KETTERERN F-18-choline and/or C-11-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (< 1 ng/mL) after radical prostatec tomy BJU INTERNATIONAL 2007 vol. 99 pp. 1415-1420 VEES H, BUCHEGGER F, ALBRECHT S, KHAN H, HUSARIK D, ZAIDI H, SOLOVIEV D, HANY TF, MIRALBELL R Radioimmunotherapy of follicular lymphoma: a step towards cure? BULLETIN DU CANCER : JOURNAL DE LA SOCIETE FRANCAISE DU CANCER 2007 vol. 94(9) pp. 799-806 KETTERER N, BISCHOF DELALOYE, HELG C, LUTHI F, BUCHEGGER F A pitfall of propidium iodide staining in fluorescence-activated cell sorting cell cycle analysis? CANCER RESEARCH 2007 vol. 67 pp. 5576-5577 BUCHEGGER F, DUPERTUIS YM, PERILLO-ADAMER F C-11-acetate PET in the early evaluation of prostate cancer recurrence EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2007 vol. 34 pp. 185-196 ALBRECHT S, BUCHEGGER F, SOLOVIEV D, ZAIDI H, VEES H, KHAN HG, KELLER A, DELALOYE AB, RATIB O, MIRALBELL R Differential tumor cell targeting of anti-HER2 (Herceptin (R)) and anti-CD20 (Mabthera (R)) coupled nanoparticles INTERNATIONAL JOURNAL OF PHARMACEUTICS 2007 vol. 331 pp. 190-196 CIRSTOIU-HAPCA A, BOSSY-NOBS L, BUCHEGGER F, GURNY R, DELIE F Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanoma NUKLEARMEDIZIN-NUCLEAR MEDICINE 2007 vol. 46(6) pp. 244-251 WILLI JP, MATTER M, BUCHEGGER F, ANTONESCU C, GUGGISBERG D, CEROTTINI JP, KRISCHER J, BRAUN R, MARIE KURT A, ROCHE B, LEMOINE R, RIMOLDI D, LEJEUNE FJ, LIÉNARD D, BISCHOF DELALOYE A Effect of an immunonutrient mix on human colorectal adenocarcinoma cell growth and viability NUTRITION 2007 vol. 23 pp. 672-680 DUPERTUIS YM, BENAIS-PONT G, BUCHEGGER F, PICHARD C Biodegradable nanoparticles for direct or two-step tumor immunotargeting BIOCONJUGATE CHEMISTRY 2006 vol. 17 pp. 139-145 NOBS L, BUCHEGGER F, GURNY R, ALLEMANN E Long-term complete responses after I-131-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma BRITISH JOURNAL OF CANCER 2006 vol. 94 pp. 1770-1776 BUCHEGGER F, ANTONESCU C, DELALOYE AB, HELG C, KOVACSOVICS T, KOSINSKI M, MACH JP, KETTERER N Auger radiation targeted into DNA: a therapy perspective EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 vol. 33 pp. 1352-1363 BUCHEGGER F, PERILLO-ADAMER F, DUPERTUIS YM, DELALOYE AB Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate I-125-iododeoxyuridine EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 vol. 33 pp. 613-620 PERILLO-ADAMER F, DELALOYE AB, GENTON CS, SCHAFFLAND AO, DUPERTUIS YM, BUCHEGGER F omega-3 Polyunsaturated fatty acids and ionizing radiation: combined cytotoxicity on human colorectal. adenocarcinoma cells NUTRITION 2006 vol. 22 pp. 931-939 BENAIS-PONT G, DUPERTUIS YM, KOSSOVSKY MP, NOUET P, ALLAL AS, BUCHEGGER F, PICHARD C Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2005 vol. 32 pp. 943-951 C. ANTONESCU, A. BISCHOF DELALOYE, M. KOSINSKI, P. MONNIN, AO SCHAFFLAND, KETTERER N, GRANNAVEL C, KOVACSOVICS T., VERDUN FR, BUCHEGGER FRANZ A new method of thermoablation with hot water vapour for localized tumors. ANTICANCER RESEARCH 2004 vol. 24 pp. 2757-2563 HILTBRAND E, BELENGER JACQUES, BINZONI TIZIANO, BUCHEGGER FRANZ, COSTA MARIA CRISTINA, MEHIER H Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2’-deoxy-2’-(fluoromethylene) cytidine and iododeoxyuridine. EUROPEAN JOURNAL OF CANCER. 2004 vol. pp. 1572-1580 COUCKE PA, COTTIN E, AZRIA D, ADAMER F, DECOSTEROD LA, BUCHEGGER FRANZ, DO HP Targeted alpha therapy in vivo : direct evidence for single cancer cell kill using 149Tb-Rituximab. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2004 vol. 31 pp. 547-554 BEYER GERD-JURGEN, MIEDERER M, VRANIES DURIE S, COMOR JJ, KUNZI G, HARTLEY OLIVER, SENEKOWITSCH-SCHMIDTKE R, SOLOVIEV D, BUCHEGGER FRANZ, ISOLDE COLLABORATION Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 2004 vol. 58 pp. 483-490 NOBS L, BUCHEGGER FRANZ, GURNY R, ALLÉMAN E Highly efficient DNA incorporation of intratumourally injected [125I]iododoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. INTERNATIONAL JOURNAL OF CANCER 2004 vol. 110 pp. 145-149 BUCHEGGER FRANZ, ADAMER FLORENCE, SCHAFFLAND A O, KOSINSKI M, GRANNAVEL C, DUPERTUIS YVES, DE TRIBOLET NICOLAS, MACH JEAN-PIERRE, BISCHOF DELALOYE A 131I-Rituximab : relationship between immunoreactivity and specific activity. JOURNAL OF NUCLEAR MEDICINE 2004 vol. 45 pp. 1784-1790 SCHAFFLAND AO, BUCHEGGER FRANZ, KOSINSKI MK, ANTONESCU C, PASCHOUD C, GRANNAVEL C, PELLIKKA R, BISCHOF DELALOYE A Current methods for attaching targeting ligands to liposomes and nanoparticles. JOURNAL OF PHARMACEUTICAL SCIENCES 2004 vol. 93 pp. 1980-1992 NOBS L, BUCHEGGER FRANZ, GURNY R, ALLÉMAN E Effect of peroxisome proliferator-activated receptor g agonist rosiglitazone on dedifferentiated thyroid cancers. NUCLEAR MEDICINE COMMUNICATIONS 2004 vol. 25 pp. 1183-1186 PHILIPS JC, PETITE CHRISTOPHE, WILLI JEAN-PIERRE, BUCHEGGER FRANZ, MEIER CHRISTOPH The preparation of clinical grade 5’[123I]-iodo-2’-deoxyuridine and 5’[125I]-iodo-2’-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy. NUCLEAR MEDICINE COMMUNICATIONS 2004 vol. 25 pp. 461-468 SCHAFFLAND AO, BISCHOF DELALOYE A, KOSINSKI M, DUPERTUIS YVES, BUCHEGGER FRANZ Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2003 vol. 30(2) pp. 239-246 BUCHEGGER F, VIEIRA JM, BLAUEUENSTEIN P, DUPERTUIS YM, SCHAFFLAND AO, GRANNAVEL C, DE TRIBOLET N, SLOSMAN D, BISCHOF DELALOYE A Radiolabeled Neurotensin analog, 99mTc-NT-XI, in ductal pancreatic adenocarcinoma patients. JOURNAL OF NUCLEAR MEDICINE 2003 vol. 44 pp. 1649-1654 BUCHEGGER F, BONVIN F, KOSINSKI M, SCHAFFLAND AO, PRIOR J, REUBI JC, BLÄUENSTEIN P, TOURWE D, GARAYOA EG, DELALOYE AB Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine CANCER RESEARCH 2001 vol. 61 pp. 7971-7977 Y. DUPERTUIS, M. VASQUEZ, J.-P. MACH, N. DE TRIBOLET, C. PICHARD, D.O. SLOSMAN, F. BUCHEGGER Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice CANCER RESEARCH 1997 vol. 57 pp. 447-453 VOGEL CA, GALMICHE MC, BUCHEGGER FRANZ Ablation of human colon carcinoma in nude mice by 131-I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab') 2 fragments JOURNAL OF CLINICAL INVESTIGATION 1989 vol. 83 pp. 1449-1456 BUCHEGGER FRANZ, PFISTER C, FOURNIER K, PREVEL F, SCHREYER M, CARREL S, MACH JEAN-PIERRE Research's domains